Literature DB >> 9139558

Using numerical results from systematic reviews in clinical practice.

H J McQuay1, R A Moore.   

Abstract

Systematic reviews summarize large amounts of information and are more likely than individual trials to describe the true clinical effect of an intervention. Traditional statistical outputs from systematic reviews cannot immediately be applied to clinical practice. The number needed to treat (NNT) has that clinical immediacy. This number can be calculated easily from raw data or from statistical outputs, and the principle involved in its calculation can be applied to different outcomes: treatment efficacy, adverse events (harm), or other end points. The NNT defines the treatment-specific effect of an intervention, and we suggest it as a currency for making decisions about individual patients. Knowing the NNT for different interventions that have the same outcome for the same disorder can help shape individual and institutional practice. Knowing or estimating the number needed to harm is also an important part of the equation. Knowing or estimating an individual patient's risk can, with the NNT, be a guide to the overall or net value of a prophylactic intervention. We advocate an approach to systematic reviews that distills information into, in effect, one number: the NNT. This is simple to remember and directly supports efforts to work with patients to make the best possible clinical decisions for their care.

Entities:  

Mesh:

Year:  1997        PMID: 9139558     DOI: 10.7326/0003-4819-126-9-199705010-00007

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  73 in total

Review 1.  Calculating the number needed to treat for trials where the outcome is time to an event.

Authors:  D G Altman; P K Andersen
Journal:  BMJ       Date:  1999-12-04

2.  Numbers needed to treat derived from meta-analysis. Are an absurdity.

Authors:  B G Charlton
Journal:  BMJ       Date:  1999-10-30

3.  Dispensing rates of four common hearing aid product features: associations with variations in practice among audiologists.

Authors:  Earl E Johnson; Todd A Ricketts
Journal:  Trends Amplif       Date:  2010-05-10

4.  Preventing stroke with ramipril. Results should have been presented in ways that help practising clinicians.

Authors:  P Badrinath
Journal:  BMJ       Date:  2002-08-24

5.  Statins and sepsis - scientifically interesting but clinically inconsequential.

Authors:  Dean T Eurich; Sumit R Majumdar
Journal:  J Gen Intern Med       Date:  2012-03       Impact factor: 5.128

6.  Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics.

Authors:  Keming Gao; David E Kemp; Elizabeth Fein; Zuowei Wang; Yiru Fang; Stephen J Ganocy; Joseph R Calabrese
Journal:  J Clin Psychiatry       Date:  2010-10-19       Impact factor: 4.384

7.  Number needed to treat (or harm).

Authors:  Martin R Tramèr; Bernhard Walder
Journal:  World J Surg       Date:  2005-05       Impact factor: 3.352

Review 8.  Comparisons of the tolerability and sensitivity of quetiapine-XR in the acute treatment of schizophrenia, bipolar mania, bipolar depression, major depressive disorder, and generalized anxiety disorder.

Authors:  Zuowei Wang; David E Kemp; Philip K Chan; Yiru Fang; Stephen J Ganocy; Joseph R Calabrese; Keming Gao
Journal:  Int J Neuropsychopharmacol       Date:  2010-09-29       Impact factor: 5.176

Review 9.  The pharmacological management of childhood anxiety disorders: a review.

Authors:  Shauna P Reinblatt; Mark A Riddle
Journal:  Psychopharmacology (Berl)       Date:  2007-01-05       Impact factor: 4.530

10.  Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis.

Authors:  Jenny Augustsson; Staffan Eksborg; Sofia Ernestam; Eleanor Gullström; Ronald van Vollenhoven
Journal:  Ann Rheum Dis       Date:  2007-05-14       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.